Opioid Analgesics

Quick Answer

Opioid analgesics are potent centrally-acting drugs that produce analgesia by binding to opioid receptors (mu, kappa, delta) in the central and peripheral nervous systems. They are mainstay agents for analgesia in critical care.

Key Concepts:

• Mu (μ) receptors: Primary mediators of analgesia, euphoria, respiratory depression, and physical dependence
• G-protein coupled mechanism: Inhibit adenylyl cyclase, reduce cAMP, open K+ channels, close Ca2+ channels
• Context-sensitive half-time: Duration of action increases with infusion duration for fentanyl but not remifentanil
• Active metabolites: Morphine-6-glucuronide (M6G) accumulates in renal failure

ICU Relevance:

• First-line agents in analgesia-first (analgosedation) protocols [1,2]
• Essential for procedural analgesia, mechanical ventilation comfort, and palliative care
• Selection based on organ function: avoid morphine in renal failure, use remifentanil for predictable offset

Exam Focus:

• Receptor pharmacology and signal transduction mechanisms
• Comparative pharmacokinetics (especially context-sensitive half-time)
• Adverse effects and their physiological basis
• Drug selection in organ dysfunction

---

CICM First Part Exam Focus

What Examiners Expect

Written SAQ:

Common question stems:

• "Describe the pharmacology of opioid receptors" (10 marks)
• "Compare and contrast morphine and fentanyl" (10 marks)
• "Outline the pharmacokinetics of remifentanil" (10 marks)
• "Describe the adverse effects of opioid analgesics" (10 marks)
• "Explain the concept of context-sensitive half-time" (10 marks)
• "Describe the mechanism and management of opioid-induced respiratory depression" (10 marks)

Expected depth:

• Molecular mechanisms at receptor level (G-protein signaling, ion channels)
• Quantitative pharmacokinetic parameters (Vd, clearance, protein binding, t½)
• Structure-activity relationships (lipophilicity and CNS penetration)
• Comparative tables for different opioid agents
• Clinical application to ICU scenarios (renal failure, hepatic impairment, obesity)

Written MCQ:

Common topics tested:

• Receptor subtypes and their effects
• Pharmacokinetic calculations (loading dose, context-sensitive half-time)
• Drug interactions (MAOIs, SSRIs, benzodiazepines)
• Equianalgesic dosing conversions
• Metabolic pathways and active metabolites

Oral Viva:

Expected discussion flow:

1. Classification: Natural, semi-synthetic, synthetic opioids
2. Receptor pharmacology: Mu, kappa, delta receptors with signal transduction
3. Individual drug profiles: Morphine, fentanyl, remifentanil with comparative PK
4. Adverse effects: Respiratory depression mechanism, tolerance, dependence
5. Clinical scenarios: Drug selection in renal failure, hepatic impairment
6. Reversal: Naloxone pharmacology and renarcotization

Common viva scenarios:

• "Tell me about the pharmacology of fentanyl"
• "What happens when you give morphine to a patient with renal failure?"
• "Explain context-sensitive half-time"
• "How would you reverse opioid-induced respiratory depression?"

Pass vs Fail Performance

Pass Standard:

• Accurate receptor classification and signal transduction
• Key pharmacokinetic parameters for major agents (morphine, fentanyl, remifentanil)
• Clear understanding of context-sensitive half-time concept
• Ability to explain adverse effects mechanistically
• Appropriate drug selection based on clinical scenario

Common Reasons for Failure:

• Confusion between receptor subtypes and their effects
• Unable to quantify pharmacokinetic parameters
• Not understanding context-sensitive half-time
• Missing active metabolite accumulation in renal failure
• No knowledge of equipotent doses

---

Key Points

10 Must-Know Facts

1. Three main opioid receptor types: Mu (μ) receptors mediate analgesia, euphoria, respiratory depression; Kappa (κ) receptors produce spinal analgesia and dysphoria; Delta (δ) receptors modulate mu receptor activity and contribute to analgesia [3,4]

2. G-protein coupled receptor mechanism: All opioid receptors are Gi/Go-coupled GPCRs. Activation inhibits adenylyl cyclase (reduces cAMP), opens K+ channels (hyperpolarization), and closes voltage-gated Ca2+ channels (reduced neurotransmitter release) [5,6]

3. Endogenous opioid peptides: Three main families - endorphins (β-endorphin from POMC, mu-selective), enkephalins (met- and leu-enkephalin, delta-selective), and dynorphins (kappa-selective) [7,8]

4. Morphine glucuronidation: Morphine is metabolized by UGT2B7 to morphine-3-glucuronide (M3G, inactive, neuroexcitatory) and morphine-6-glucuronide (M6G, active, 10-45× more potent than morphine). Both accumulate in renal failure [9,10]

5. Fentanyl lipophilicity: Fentanyl is 100× more potent than morphine with high lipophilicity (octanol:water partition coefficient ~800), rapid CNS penetration, and large Vd (4 L/kg). Context-sensitive half-time increases significantly with prolonged infusion [11,12]

6. Remifentanil ester hydrolysis: Unique metabolism by non-specific tissue esterases (NOT plasma cholinesterase). Context-sensitive half-time remains 3-4 minutes regardless of infusion duration. Causes acute opioid tolerance and opioid-induced hyperalgesia (OIH) [13,14]

7. Context-sensitive half-time: Time for plasma concentration to decrease by 50% after stopping an infusion. Depends on infusion duration, Vd, and clearance. Critical for predicting offset in ICU [15,16]

8. Respiratory depression mechanism: Opioids depress the ventilatory response to CO2 and hypoxia by acting on mu receptors in the pre-Bötzinger complex (respiratory rhythm generator) and nucleus tractus solitarius. Dose-dependent reduction in respiratory rate, tidal volume, and minute ventilation [17,18]

9. Methadone NMDA antagonism: Methadone is a mu agonist with additional NMDA receptor antagonism and norepinephrine/serotonin reuptake inhibition. Long, unpredictable half-life (15-60 hours). Causes QT prolongation via hERG channel blockade [19,20]

10. Naloxone pharmacology: Competitive mu receptor antagonist with shorter duration (30-90 minutes) than most opioids. Risk of renarcotization requires observation/infusion. Titrate to respiratory rate, not consciousness, to avoid withdrawal [21,22]

Essential Equations

Equation 1: Loading Dose

Loading Dose = Vd × Target Concentration

• Example: Fentanyl Vd = 4 L/kg, Target = 2 ng/mL
• Loading dose = 4 × 70 × 2 = 560 μg (approximately 8 μg/kg)

Equation 2: Maintenance Infusion Rate

Infusion Rate = Clearance × Target Concentration (at steady state)

• Example: Fentanyl clearance = 13 mL/kg/min
• Infusion = 13 × 70 × 2 = 1820 ng/min = 1.82 μg/min ≈ 110 μg/hr

Equation 3: Context-Sensitive Half-Time Estimation

t½cs = f(duration, Vd, CL, redistribution)

• Not a simple calculation; derived from compartmental models
• Remifentanil: 3-4 min (constant)
• Alfentanil: 50 min (4-hour infusion)
• Fentanyl: 300 min (8-hour infusion)

Normal Values Table

---

Opioid Receptor Pharmacology

Overview of Opioid Receptors

Opioid receptors are G-protein coupled receptors (GPCRs) belonging to the Class A rhodopsin family. They are distributed throughout the central and peripheral nervous systems and mediate the analgesic, euphoric, and adverse effects of opioids. [3,4,23]

The three classical opioid receptor types were named after the prototype ligands used in their discovery:

• Mu (μ): Named for morphine
• Kappa (κ): Named for ketocyclazocine
• Delta (δ): Named for vas deferens (tissue of discovery)

A fourth receptor, the nociceptin/orphanin FQ receptor (NOP, ORL-1), shares structural homology but has distinct pharmacology and is not activated by classical opioids. [24]

Mu (μ) Opioid Receptors

Location:

• Supraspinal: Periaqueductal gray (PAG), rostral ventromedial medulla (RVM), thalamus, amygdala, nucleus accumbens
• Spinal: Substantia gelatinosa (laminae I and II of dorsal horn)
• Peripheral: Primary afferent nociceptors, gastrointestinal tract

Effects of Mu Receptor Activation:

Receptor Subtypes:

• μ1: Supraspinal analgesia, euphoria
• μ2: Spinal analgesia, respiratory depression, constipation, dependence

Signal Transduction (detailed below) [5,6]

Kappa (κ) Opioid Receptors

Location:

• Spinal cord (substantia gelatinosa)
• Hypothalamus
• Periaqueductal gray
• Claustrum

Effects of Kappa Receptor Activation:

Clinical Relevance:

• Kappa agonists (pentazocine, butorphanol, nalbuphine) produce analgesia with less respiratory depression than mu agonists
• Dysphoria limits clinical utility as sole analgesics
• Ceiling effect on respiratory depression
• Useful in obstetrics (less neonatal respiratory depression)

Delta (δ) Opioid Receptors

Location:

• Pontine nuclei
• Amygdala
• Olfactory bulb
• Deep cortex
• Peripheral sensory neurons

Effects of Delta Receptor Activation:

Clinical Relevance:

• No clinically available selective delta agonists
• Delta receptors modulate mu receptor function
• May be targets for future opioid development with improved safety profile
• Enkephalins are endogenous delta ligands

G-Protein Coupled Receptor Signal Transduction

All opioid receptors signal through inhibitory G-proteins (Gi/Go). Activation produces multiple downstream effects: [5,6,25]

Step 1: Receptor Activation

• Agonist binding induces conformational change in receptor
• Receptor couples to heterotrimeric G-protein (αβγ subunits)

Step 2: G-Protein Activation

• GDP-GTP exchange on Gα subunit
• Dissociation of Gα-GTP from Gβγ dimer
• Both subunits exert effector actions

Step 3: Effector Modulation

Step 4: Neuronal Effects

• Presynaptic: Reduced neurotransmitter release (substance P, glutamate, CGRP)
• Postsynaptic: Hyperpolarization, reduced neuronal excitability
• Net effect: Inhibition of nociceptive transmission

Receptor Desensitization and Tolerance:

• Phosphorylation by G-protein coupled receptor kinases (GRKs)
• β-arrestin recruitment and receptor internalization
• Reduced receptor density (downregulation)
• Cellular adaptations (increased adenylyl cyclase activity)
• Basis for opioid tolerance development [26,27]

Receptor Affinity and Efficacy

Agonist Classification:

Clinical Implications:

• Partial agonists have ceiling effect on respiratory depression
• Mixed agonist-antagonists may precipitate withdrawal in opioid-dependent patients
• Buprenorphine's high receptor affinity makes reversal with naloxone difficult

---

Endogenous Opioid System

Endogenous Opioid Peptides

The endogenous opioid system modulates pain, reward, and stress responses through three main peptide families: [7,8,28]

1. Endorphins (Endogenous morphine-like compounds)

• POMC is cleaved to produce ACTH, MSH, and β-endorphin
• β-endorphin (31 amino acids) is the most potent endogenous opioid
• Released during stress, exercise, pain
• Important in descending pain modulation (PAG → RVM → spinal cord)

2. Enkephalins

• Pentapeptides (Tyr-Gly-Gly-Phe-Met or Leu)
• Short half-life due to rapid enzymatic degradation (aminopeptidases, enkephalinases)
• Co-released with norepinephrine from adrenal medulla
• Important in local spinal cord modulation

3. Dynorphins

• Derived from prodynorphin (proenkephalin B)
• Potent kappa agonists
• Involved in stress, dysphoria, and spinal analgesia
• May contribute to stress-induced analgesia

Physiological Functions of Endogenous Opioids

---

Individual Opioid Agents

Morphine

Morphine is the prototype opioid analgesic, derived from the opium poppy (Papaver somniferum). It remains a standard for comparison of other opioids. [9,10,29]

Pharmacodynamics

Receptor Activity:

• Full mu agonist (primary action)
• Weak kappa agonist
• Minimal delta activity

Clinical Effects:

• Analgesia (supraspinal and spinal)
• Sedation
• Euphoria
• Respiratory depression
• Nausea/vomiting (via CTZ)
• Histamine release (direct mast cell degranulation)
• Pruritus
• Miosis
• Constipation
• Urinary retention
• Bradycardia (vagal stimulation)

Pharmacokinetics

Metabolism:

• Primary: Hepatic glucuronidation by UGT2B7
• Metabolites:
  • "Morphine-3-glucuronide (M3G): 55-75% of dose; inactive analgesic; neuroexcitatory (may cause myoclonus, allodynia) [30]"
  • "Morphine-6-glucuronide (M6G): 10-15% of dose; active; 10-45× more potent than morphine at mu receptors"
  • Both metabolites are renally excreted

Histamine Release:

• Morphine causes direct mast cell degranulation (non-IgE mediated)
• Clinical effects: vasodilation, hypotension, flushing, pruritus, bronchospasm
• More pronounced with rapid IV bolus
• Fentanyl and synthetic opioids do NOT cause histamine release [31]

Clinical Considerations

Renal Failure:

• M3G and M6G accumulate with reduced GFR
• M6G accumulation causes prolonged sedation, respiratory depression
• Avoid morphine in CKD Stage 4-5 (GFR <30 mL/min) [32]
• Use hydromorphone or fentanyl instead

Hepatic Impairment:

• Glucuronidation relatively preserved until severe liver failure
• Reduce dose by 50% in Child-Pugh C
• Consider hydromorphone (more predictable metabolism)

Obesity:

• Dose based on lean body weight (LBW)
• Vd minimally affected (hydrophilic drug)

Equianalgesic Dosing:

• IV morphine 10 mg = oral morphine 30 mg
• IV morphine 10 mg = IV fentanyl 100 μg
• IV morphine 10 mg = IV hydromorphone 1.5 mg

Fentanyl

Fentanyl is a highly potent, lipophilic synthetic opioid widely used in anesthesia and intensive care. [11,12,33,34]

Pharmacodynamics

Receptor Activity:

• Full mu agonist (high affinity)
• Minimal kappa and delta activity
• 100× more potent than morphine

Structure-Activity Relationship:

• Phenylpiperidine derivative
• High lipophilicity (octanol:water partition coefficient ~800)
• Rapid CNS penetration due to lipophilicity and low degree of ionization
• Does NOT cause histamine release

Pharmacokinetics

Three-Compartment Model:

• Central compartment: Plasma and highly perfused tissues
• Rapid equilibrating compartment: Muscle
• Slow equilibrating compartment: Fat (depot)

Redistribution:

• Rapid initial decline due to redistribution to muscle and fat
• Slow return from fat depot during prolonged infusion
• Explains increasing context-sensitive half-time with infusion duration

Metabolism:

• Primary: Hepatic CYP3A4 to norfentanyl (inactive)
• Other metabolites: Hydroxyfentanyl, hydroxynorfentanyl (all inactive)
• <10% excreted unchanged in urine
• No active metabolites

Context-Sensitive Half-Time (key concept for ICU):

This prolongation is due to:

1. Saturation of peripheral tissue compartments
2. Slow return of drug from fat depot
3. Reduced concentration gradient for elimination

Clinical Considerations

Chest Wall Rigidity (Wooden Chest Syndrome):

• Increased muscle tone of chest wall, abdominal wall, and larynx
• Mechanism: Central effect (not neuromuscular junction); involves nucleus raphe and striatum [35]
• Risk factors: High dose, rapid IV injection, elderly, concurrent opioid use
• Management: Stop infusion, muscle relaxant (succinylcholine or rocuronium), ventilate, naloxone (partial reversal)
• Prevention: Slow injection, pretreatment with muscle relaxant

Hemodynamic Stability:

• Minimal histamine release
• No direct myocardial depression at clinical doses
• Maintains hemodynamic stability
• Ideal for cardiovascular instability

Renal Failure:

• No active metabolites
• Minimal dose adjustment required
• Preferred opioid in ESRD [36]

Hepatic Impairment:

• Reduced clearance with severe hepatic dysfunction
• Consider dose reduction in Child-Pugh C
• Monitor for accumulation

Drug Interactions:

• CYP3A4 inhibitors (fluconazole, erythromycin, ritonavir) increase fentanyl levels
• CYP3A4 inducers (rifampicin, carbamazepine, phenytoin) decrease fentanyl levels

Remifentanil

Remifentanil is a unique ultra-short-acting synthetic opioid with ester linkage enabling rapid hydrolysis by non-specific tissue esterases. [13,14,37,38]

Pharmacodynamics

Receptor Activity:

• Full mu agonist
• 200× more potent than morphine
• Similar effect profile to fentanyl

Pharmacokinetics

Unique Metabolism:

• Hydrolyzed by non-specific tissue esterases (NOT plasma cholinesterase)
• Present in blood, tissues, and interstitial fluid
• Unaffected by plasma cholinesterase deficiency (atypical BChE)
• Metabolite: Remifentanil acid (GR90291) - 0.1-0.3% potency, renally excreted
• Organ-independent metabolism (not hepatic or renal)

Context-Sensitive Half-Time:

• Remains 3-4 minutes regardless of infusion duration (1 hour to 10 hours)
• No accumulation
• Rapid, predictable offset
• Ideal for procedures requiring rapid neurological assessment

Clinical Considerations

Acute Opioid Tolerance and Opioid-Induced Hyperalgesia (OIH):

• Remifentanil uniquely associated with rapid tolerance development [39,40]
• OIH: Paradoxical increased pain sensitivity after remifentanil exposure
• Mechanisms:
  • Rapid mu receptor desensitization and internalization
  • NMDA receptor upregulation
  • Spinal cord sensitization
• Prevention:
  • Limit infusion duration
  • Transitional analgesia before cessation (long-acting opioid or regional technique)
  • Consider ketamine co-administration (NMDA antagonism)

Advantages in ICU:

• Predictable offset for neurological assessment
• No accumulation in renal or hepatic failure
• Easy titration for procedures
• Daily sedation interruption (wake-up testing)

Disadvantages:

• Requires continuous infusion (no residual effect)
• Hypotension with bolus doses (vagal stimulation)
• Acute tolerance
• Cost
• No post-infusion analgesia (must transition before stopping)

Dosing in ICU:

• Analgosedation: 0.05-0.2 μg/kg/min
• Procedural: 0.5-1 μg/kg bolus + 0.25-0.5 μg/kg/min infusion
• Must provide transitional analgesia before discontinuation

Alfentanil

Alfentanil is a synthetic opioid with intermediate characteristics between fentanyl and remifentanil. [41,42]

Pharmacokinetics

Comparison with Fentanyl:

• Lower Vd → less redistribution → faster offset after short infusion
• Lower pKa → more un-ionized → faster onset
• Context-sensitive t½ shorter than fentanyl for infusions <4 hours
• For very prolonged infusions, fentanyl and alfentanil context-sensitive t½ converge

Clinical Use:

• Short procedures requiring rapid onset and offset
• Rarely used in prolonged ICU sedation
• Useful for procedural sedation (bronchoscopy, central line placement)

Hydromorphone

Hydromorphone is a semi-synthetic opioid derived from morphine with improved pharmacokinetic profile in renal failure. [43,44]

Pharmacodynamics

Receptor Activity:

• Full mu agonist
• 5-7× more potent than morphine (parenteral)
• Does NOT cause histamine release

Pharmacokinetics

Metabolism:

• Primary: Hepatic glucuronidation (UGT1A3, UGT2B7)
• Metabolites:
  • "Hydromorphone-3-glucuronide (H3G): Major metabolite; neuroexcitatory (similar to M3G)"
  • "Dihydromorphine: Minor metabolite"
  • NO active analgesic metabolite (unlike morphine's M6G)

Clinical Considerations

Renal Failure:

• H3G accumulates but does NOT cause prolonged analgesia/sedation (unlike M6G)
• H3G may contribute to neurotoxicity (myoclonus, seizures) with severe accumulation
• Preferred over morphine in moderate renal impairment (GFR 30-60 mL/min)
• In severe renal failure (GFR <30), fentanyl remains first choice

Advantages:

• No histamine release
• Lower injection volume (higher potency)
• More predictable in renal impairment than morphine
• Available in high-concentration formulations

Equianalgesic Dosing:

• IV morphine 10 mg = IV hydromorphone 1.5 mg
• Oral morphine 30 mg = oral hydromorphone 6 mg

Methadone

Methadone is a synthetic opioid with unique pharmacology including mu agonism, NMDA antagonism, and monoamine reuptake inhibition. [19,20,45,46]

Pharmacodynamics

Receptor Activity:

• Full mu agonist
• NMDA receptor antagonist (useful for neuropathic pain, tolerance prevention)
• Serotonin and norepinephrine reuptake inhibitor (SNRI-like activity)

Unique Properties:

• NMDA antagonism may prevent opioid tolerance
• Useful in neuropathic pain (where pure mu agonists are less effective)
• Long duration allows once-daily dosing (opioid maintenance programs)

Pharmacokinetics

Metabolism:

• Hepatic CYP3A4 (primary), CYP2B6, CYP2D6
• Active metabolites: Minimal
• Highly variable pharmacokinetics between individuals

Clinical Considerations

QT Prolongation:

• Methadone blocks hERG potassium channels (IKr)
• Dose-dependent QT prolongation
• Risk of Torsades de Pointes [47,48]
• Risk factors: Doses >100 mg/day, hypokalemia, hypomagnesemia, concurrent QT-prolonging drugs
• Monitoring: Baseline and periodic ECG; target QTc <500 ms

ICU Applications:

• Difficult-to-control pain (neuropathic component)
• Prevention of opioid tolerance (NMDA antagonism)
• Facilitation of weaning from high-dose opioid infusions
• Iatrogenic withdrawal prevention

Drug Interactions (extensive):

• CYP3A4 inhibitors increase methadone levels
• CYP3A4 inducers decrease methadone levels
• Additive QT prolongation with other drugs

Dosing Challenges:

• Unpredictable half-life (15-60 hours)
• Risk of delayed toxicity with repeat dosing
• Requires careful titration and monitoring
• Not suitable for PRN or rapid titration

Tramadol

Tramadol is an atypical opioid analgesic with weak mu agonism and monoamine reuptake inhibition. [49,50,51]

Pharmacodynamics

Dual Mechanism of Action:

1. Mu opioid agonism: Weak affinity (6000× less than morphine)
2. Monoamine reuptake inhibition:
   • Serotonin reuptake inhibition (SSRI-like)
   • Norepinephrine reuptake inhibition (SNRI-like)
   • Contributes to analgesia and adverse effects

Active Metabolite:

• O-desmethyltramadol (M1): CYP2D6 metabolite
• 200× more potent at mu receptor than parent compound
• Primary source of opioid analgesic effect

Pharmacokinetics

CYP2D6 Polymorphism (critical):

• Poor metabolizers (5-10% Caucasians): Minimal M1 formation → reduced analgesia, increased parent effects (SNRI side effects)
• Ultrarapid metabolizers (1-10%): Excessive M1 formation → opioid toxicity risk

Clinical Considerations

Seizure Risk:

• Tramadol lowers seizure threshold
• Risk increases with: doses >400 mg/day, renal impairment, concurrent SSRIs/SNRIs, seizure history
• Contraindicated in uncontrolled epilepsy [52]

Serotonin Syndrome:

• Risk with concurrent SSRIs, SNRIs, MAOIs, triptans
• Symptoms: agitation, hyperthermia, tremor, clonus, diaphoresis
• Avoid combination with serotonergic drugs in ICU [53]

Ceiling Effect:

• Maximum recommended dose: 400 mg/day
• Limited analgesia for severe pain
• Not recommended as sole analgesic in ICU

Advantages:

• Less respiratory depression than pure mu agonists
• Less constipation
• Lower addiction potential
• Oral formulation widely available

ICU Role:

• Step-down analgesia (ICU to ward transition)
• Mild-moderate pain (not primary ICU analgesic)
• Multimodal analgesia adjunct

---

Opioid Pharmacokinetics: Comparative Analysis

Context-Sensitive Half-Time

Context-sensitive half-time (CSHT) is the time required for plasma concentration to decrease by 50% after stopping an infusion of a given duration. It is more clinically relevant than terminal half-life for predicting drug offset. [15,16]

Determinants of Context-Sensitive Half-Time:

1. Volume of distribution: Large Vd leads to tissue accumulation and slow return
2. Clearance: Higher clearance accelerates elimination
3. Peripheral compartment equilibration: Slow equilibrating compartments (fat) release drug slowly
4. Infusion duration: Longer infusions allow greater tissue loading

Graphical Representation:

Context-Sensitive Half-Time (minutes)
|
400│                                    ____Fentanyl
   │                               ____/
300│                          ____/
   │                     ____/
200│                ____/_________ Morphine
   │           ____/     ________ Alfentanil
100│      ____/    _____/
   │  ___/    ____/
  0│_/_____________________________ Remifentanil
   └──────────────────────────────────
   0        2        4        6        8   Infusion Duration (hours)

Clinical Implications:

Lipophilicity and CNS Penetration

Effect-Site Equilibration:

The rate of CNS penetration depends on:

1. Lipophilicity: Higher = faster BBB crossing
2. Degree of ionization: Un-ionized drug crosses more readily
3. Protein binding: Only free drug crosses BBB
4. Cerebral blood flow: Affects delivery

Alfentanil Paradox:

• Despite lower lipophilicity than fentanyl, alfentanil has faster onset
• Explained by higher fraction un-ionized at pH 7.4 (89% vs 9%)
• Less protein binding contributing to higher free fraction

Protein Binding Considerations

Clinical Pearl: In sepsis and inflammation, alpha-1-acid glycoprotein (AAG) increases as an acute phase reactant. This can reduce the free fraction of highly protein-bound opioids (fentanyl, alfentanil), potentially reducing efficacy. However, the increased Vd from capillary leak syndrome often counterbalances this effect.

---

Adverse Effects

Respiratory Depression

Opioid-induced respiratory depression is the most dangerous adverse effect and the primary cause of opioid-related mortality. [17,18,54]

Mechanism:

1. Pre-Bötzinger Complex: Mu receptors in this medullary nucleus (respiratory rhythm generator) are hyperpolarized, reducing pacemaker activity
2. Nucleus Tractus Solitarius (NTS): Reduced CO2 chemosensitivity
3. Carotid Body: Blunted hypoxic ventilatory response
4. Effects:
   • Reduced respiratory rate (primary effect)
   • Reduced tidal volume
   • Shift of CO2 response curve rightward (higher CO2 needed to stimulate breathing)
   • Obliteration of hypoxic drive (dangerous in COPD patients)

Clinical Manifestations:

• Reduced respiratory rate (<10/min) → most sensitive early sign
• Reduced tidal volume
• Hypercapnia (increased PaCO2)
• Hypoxemia (late sign)
• Obtundation
• Respiratory arrest

Risk Factors:

• Opioid-naïve patients
• Concurrent sedatives (benzodiazepines, propofol)
• Sleep apnea (obstructive or central)
• Elderly
• Hepatic/renal impairment (accumulation)
• Respiratory disease (reduced reserve)

Prevention in ICU:

• Titrate to effect (not fixed dosing)
• Monitor respiratory rate, depth, sedation score
• Capnography in high-risk patients
• Avoid combinations with sedatives when possible
• Consider partial agonists (buprenorphine) for high-risk patients

Cardiovascular Effects

Gastrointestinal Effects

Opioid-Induced Constipation (OIC):

• Occurs in 40-95% of patients on chronic opioids
• Does NOT develop tolerance (unlike other effects)
• Management:
  • Prophylactic laxatives (stimulant + osmotic)
  • Methylnaltrexone (peripheral mu antagonist; does not cross BBB)
  • Naloxegol (oral peripheral antagonist)

Pruritus

Mechanism:

• Central (primary): Mu receptor activation in spinal cord and nucleus of trigeminal nerve
• NOT primarily histamine-mediated (distinguishing from morphine's histamine release)
• More common with neuraxial administration

Management:

• Opioid rotation (try different agent)
• Low-dose naloxone infusion (0.25-1 μg/kg/hr)
• Ondansetron (5-HT3 antagonist; may modulate central pruritus)
• Antihistamines have limited efficacy (central mechanism)

Urinary Retention

Mechanism:

• Mu receptor activation in sacral spinal cord
• Increased external urethral sphincter tone
• Detrusor muscle relaxation
• More common with neuraxial opioids

Management:

• Bladder catheterization
• Reduce opioid dose
• Consider opioid rotation

Tolerance and Dependence

Tolerance:

• Reduced effect with repeated administration; need for dose escalation
• Develops to: analgesia, euphoria, sedation, respiratory depression, nausea
• Does NOT develop to: miosis, constipation
• Mechanism: Receptor desensitization, downregulation, altered signal transduction [26,27]

Physical Dependence:

• Physiological adaptation to chronic opioid exposure
• Manifests as withdrawal syndrome on cessation
• Distinct from addiction (behavioral disorder)
• Withdrawal: Agitation, tachycardia, hypertension, diaphoresis, mydriasis, diarrhea, piloerection

Opioid-Induced Hyperalgesia (OIH) [39,40]:

• Paradoxical increase in pain sensitivity
• Distinct from tolerance (increased pain, not just reduced analgesia)
• More common with remifentanil, high doses, prolonged use
• Mechanism: NMDA receptor upregulation, spinal cord sensitization
• Management: Dose reduction (not increase), opioid rotation, NMDA antagonists (ketamine)

---

Naloxone Reversal

Pharmacology of Naloxone

Naloxone is a competitive opioid receptor antagonist used to reverse opioid effects. [21,22,55,56]

Receptor Activity:

• Competitive antagonist at mu, kappa, and delta receptors
• Highest affinity for mu receptors
• No intrinsic activity (pure antagonist)

Pharmacokinetics:

Clinical Use

Indications:

• Reversal of opioid-induced respiratory depression
• Opioid overdose (accidental or intentional)
• Neonatal resuscitation (opioid-exposed)
• Diagnosis of suspected opioid intoxication

Dosing Strategy:

Initial Titration (to restore ventilation, not consciousness):

• Start: 0.04-0.1 mg IV (40-100 μg)
• Repeat every 2-3 minutes if needed
• Goal: Respiratory rate >12/min, adequate oxygenation
• Avoid complete reversal (preserves some analgesia)

Higher Doses (when full reversal needed):

• 0.4-2 mg IV if partial doses ineffective
• Up to 10 mg if no response (reconsider diagnosis)

Continuous Infusion (Goldfrank protocol):

• Indication: Long-acting opioids (methadone), massive overdose
• Dose: Two-thirds of initial bolus dose per hour
• Example: If 0.3 mg bolus effective → infuse 0.2 mg/hour
• Duration: 12-24+ hours depending on opioid half-life
• Monitor for breakthrough respiratory depression

Renarcotization

Definition: Return of opioid effects after naloxone wears off

Risk Factors:

• Long-acting opioid (methadone, sustained-release formulations)
• Large opioid dose
• Hepatic impairment (reduced opioid clearance)
• Inadequate naloxone dose or single bolus only

Prevention:

• Observation for at least 4 hours post single dose
• Continuous naloxone infusion for long-acting opioids
• Repeat dosing as needed
• Consider hospital admission for intentional overdose

Special Considerations

Opioid-Dependent Patients:

• Full reversal precipitates acute withdrawal
• Start with very low doses (0.04 mg)
• Titrate to respiratory improvement only
• Withdrawal symptoms: Agitation, hypertension, tachycardia, vomiting, diarrhea

Buprenorphine Reversal:

• High receptor affinity makes displacement difficult
• Higher naloxone doses required (10-35 mg may be needed)
• Consider doxapram (respiratory stimulant) as adjunct

Synthetic Opioids (Carfentanil):

• Extremely high potency (10,000× morphine)
• May require very high naloxone doses
• Prolonged observation (24-48 hours)

---

Clinical Applications in ICU

Analgosedation (Analgesia-First) Approach

The PADIS guidelines (2018) recommend an analgesia-first approach to sedation in mechanically ventilated adults. [1,2]

Principles:

1. Treat pain first before adding sedatives
2. Use opioid infusions for analgesia
3. Add sedatives only if needed for agitation/anxiety after adequate analgesia
4. Target light sedation (RASS 0 to -2)
5. Daily sedation interruption

Evidence Supporting Analgosedation:

• Reduced mechanical ventilation duration
• Reduced ICU length of stay
• Reduced delirium incidence
• Reduced total sedative requirements
• Improved patient comfort and recall

Opioid Selection for Analgosedation:

Patient-Controlled Analgesia (PCA)

Components:

• Demand dose (bolus)
• Lockout interval (minimum time between doses)
• Background infusion (optional; increases oversedation risk)
• 4-hour maximum dose

Typical Morphine PCA Settings:

• Demand dose: 1-2 mg
• Lockout interval: 6-10 minutes
• 4-hour maximum: 30-40 mg
• Background infusion: Usually avoided in opioid-naïve

Advantages:

• Patient autonomy
• Titrated to individual needs
• Avoids peaks and troughs of PRN dosing
• Useful for acute pain, post-operative, burns

Contraindications:

• Altered consciousness
• Unable to understand/operate device
• Cognitive impairment
• Severe respiratory disease

Regional Analgesia Techniques

Neuraxial Opioids:

• Epidural: Morphine, fentanyl, sufentanil
• Intrathecal: Morphine (gold standard for post-cardiac surgery)
• Provide excellent analgesia with lower systemic doses
• Risk: Delayed respiratory depression (especially hydrophilic morphine)

Peripheral Nerve Blocks:

• Reduce opioid requirements
• Improved analgesia with fewer systemic effects
• Examples: Femoral nerve block, TAP block, erector spinae block

Opioid-Free Analgesia (OFA)

Emerging approach using multimodal non-opioid analgesics: [57,58]

Components:

• Ketamine (NMDA antagonist)
• Dexmedetomidine (alpha-2 agonist)
• Lidocaine infusion
• NSAIDs (ketorolac, parecoxib)
• Paracetamol
• Regional analgesia

Rationale:

• Avoid opioid-related adverse effects
• Reduce opioid tolerance and hyperalgesia
• May benefit patients with history of opioid use disorder
• Potentially reduced ileus, nausea, respiratory depression

Current Evidence:

• Limited high-quality evidence in ICU
• May be suitable for select patients
• Not yet standard of care
• Opioids remain mainstay for severe ICU pain

---

Australian/NZ Context

Drug Scheduling

Schedule 8 (S8) Drugs:

• Controlled substances requiring additional regulatory oversight
• All opioid analgesics covered in this chapter are S8
• Requirements: Secure storage, register of administration, prescription limits
• State/territory variations in specific requirements

PBS Listings

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples:

Pain management in Indigenous communities requires cultural competence: [59,60]

• Health disparities: Higher rates of chronic disease, trauma, and pain conditions
• Access barriers: Remote communities may have limited access to pain specialists
• Cultural considerations:
  • Involve Aboriginal Health Workers (AHWs) or Aboriginal Liaison Officers (ALOs)
  • Family-centered decision-making
  • Explain medication purpose, effects, and safety in culturally appropriate language
  • Consider health literacy levels
  • Respect for traditional medicine and healing practices
• Opioid prescribing concerns:
  • Higher rates of prescription opioid misuse in some communities
  • Balance adequate pain management with harm minimization
  • Consider non-pharmacological approaches
  • Engage community health services in care planning

Māori Health (New Zealand):

• Whānau (family) involvement in care decisions
• Tikanga (customs) considerations
• Access to Māori health providers
• Addressing health inequities in pain management
• Cultural safety in communication about addiction risk

Remote and Rural Considerations

RFDS (Royal Flying Doctor Service) Protocols:

• Limited drug availability in remote areas
• Oral opioids may be primary option
• Ketamine as adjunct when opioids limited
• Telemedicine consultation for complex cases

Retrieval Medicine:

• Fentanyl preferred for hemodynamic stability during transport
• Ketamine for analgosedation in retrieval
• Limited monitoring capabilities
• Weight-based protocols for non-ICU personnel

---

SAQ Practice Questions

SAQ 1: Opioid Receptor Pharmacology (15 marks)

Question:

A 55-year-old man is receiving a fentanyl infusion in the ICU for analgosedation following major abdominal surgery. He develops respiratory depression with a respiratory rate of 6 breaths/minute and oxygen saturation of 88% on room air.

1.1 Describe the mechanism of opioid-induced respiratory depression at the receptor and cellular level. (6 marks)

1.2 Compare and contrast the three main opioid receptor types and their effects. (5 marks)

1.3 Outline the pharmacology of naloxone and describe how you would use it in this patient. (4 marks)

---

Model Answer:

1.1 Mechanism of Opioid-Induced Respiratory Depression (6 marks)

Receptor level (2 marks):

• Mu (μ) opioid receptors in respiratory control centers
• Primary sites: Pre-Bötzinger complex (respiratory rhythm generator), nucleus tractus solitarius (CO2 chemosensitivity)

Cellular/Molecular mechanism (2 marks):

• Mu receptors are Gi/Go-coupled GPCRs
• Activation inhibits adenylyl cyclase → reduced cAMP
• Opens GIRK K+ channels → neuronal hyperpolarization
• Closes voltage-gated Ca2+ channels → reduced neurotransmitter release

Physiological effects (2 marks):

• Reduced respiratory rate (primary effect) - depression of pacemaker activity
• Rightward shift of CO2 response curve (higher CO2 needed to stimulate breathing)
• Blunted hypoxic ventilatory response
• Reduced tidal volume

1.2 Comparison of Opioid Receptor Types (5 marks)

1.3 Naloxone Pharmacology and Use (4 marks)

Pharmacology (2 marks):

• Competitive antagonist at all opioid receptors (highest affinity for mu)
• Onset: 1-2 minutes IV
• Duration: 30-90 minutes (SHORTER than most opioids)
• t½: 30-90 minutes

Use in this patient (2 marks):

• Initial dose: 0.04-0.1 mg IV (low dose to avoid complete reversal)
• Repeat every 2-3 minutes until RR >12/min
• Target respiratory improvement, NOT full arousal (preserves analgesia)
• Consider infusion (two-thirds of bolus dose per hour) due to fentanyl's long duration
• Observe for renarcotization as naloxone wears off

---

SAQ 2: Comparative Pharmacokinetics (15 marks)

Question:

A 70-year-old woman with chronic kidney disease (GFR 20 mL/min) requires opioid analgesia in the ICU following emergency laparotomy for bowel obstruction.

2.1 Compare the pharmacokinetics of morphine and fentanyl, including the clinical significance of context-sensitive half-time. (6 marks)

2.2 Explain why morphine is relatively contraindicated in this patient and recommend an alternative opioid with justification. (5 marks)

2.3 Describe the concept of opioid-induced hyperalgesia and the opioid most associated with this phenomenon. (4 marks)

---

Model Answer:

2.1 Pharmacokinetic Comparison (6 marks)

Context-sensitive half-time (2 marks):

• Definition: Time for plasma concentration to fall 50% after stopping an infusion
• More clinically relevant than terminal t½ for predicting offset
• Depends on infusion duration, Vd, clearance, tissue accumulation

Clinical significance: Fentanyl accumulates more with prolonged infusion due to large Vd and slow redistribution from fat.

2.2 Morphine Contraindication and Alternative (5 marks)

Why morphine is contraindicated (2 marks):

• Morphine-6-glucuronide (M6G) is an active metabolite (10-45× potency of morphine)
• M6G is renally excreted; accumulates in renal failure (GFR <30 mL/min)
• Causes prolonged sedation, respiratory depression
• Morphine-3-glucuronide (M3G) also accumulates; neuroexcitatory (myoclonus, allodynia)

Alternative recommendation: Fentanyl (3 marks):

• No active metabolites (norfentanyl is inactive)
• Hepatic metabolism (CYP3A4), not dependent on renal excretion
• Minimal dose adjustment required in renal failure
• No histamine release (hemodynamic stability)
• Alternative: Hydromorphone (no active analgesic metabolite, though H3G may accumulate)

2.3 Opioid-Induced Hyperalgesia (OIH) (4 marks)

Definition (1 mark):

• Paradoxical increase in pain sensitivity caused by opioid exposure
• Distinct from tolerance (not just reduced analgesia, but increased pain)

Mechanism (2 marks):

• NMDA receptor upregulation in spinal cord
• Central sensitization
• Enhanced pronociceptive neurotransmission
• Glial cell activation

Associated opioid (1 mark):

• Remifentanil is most associated with OIH
• Rapid offset and receptor kinetics promote neuroplastic changes
• Prevention: Limit duration, transitional analgesia, ketamine co-administration (NMDA antagonist)

---

Viva Scenarios

Viva Scenario 1: Fentanyl Pharmacology

Setting: Cross-table viva, 10 minutes

Examiner: "Tell me about the pharmacology of fentanyl."

Candidate: "Fentanyl is a highly potent, lipophilic synthetic opioid that is widely used in anesthesia and intensive care for analgesia and sedation."

"Starting with pharmacodynamics, fentanyl is a full agonist at mu opioid receptors, with minimal activity at kappa and delta receptors. It is approximately 100 times more potent than morphine."

"The mechanism of action involves activation of Gi/Go-coupled receptors, leading to inhibition of adenylyl cyclase, opening of potassium channels causing hyperpolarization, and closure of voltage-gated calcium channels reducing neurotransmitter release."

---

Examiner: "What are the key pharmacokinetic properties of fentanyl?"

Candidate: "Fentanyl has several distinctive pharmacokinetic properties:

The pKa is 8.4, meaning only 9% is un-ionized at physiological pH 7.4. However, despite this low un-ionized fraction, its extremely high lipophilicity (octanol:water partition coefficient of approximately 800) allows rapid penetration of the blood-brain barrier.

Protein binding is 80-85%, primarily to alpha-1-acid glycoprotein.

The volume of distribution is large at 4 L/kg, reflecting extensive tissue distribution, particularly to fat and muscle.

Clearance is 10-20 mL/kg/min, occurring primarily through hepatic CYP3A4 metabolism to inactive norfentanyl.

Importantly, fentanyl has NO active metabolites, which makes it preferable in renal failure."

---

Examiner: "Explain context-sensitive half-time and how it applies to fentanyl."

Candidate: "Context-sensitive half-time is the time required for plasma concentration to decrease by 50% after stopping a continuous infusion. Unlike terminal half-life, it accounts for drug redistribution and is more clinically relevant for predicting offset.

For fentanyl, context-sensitive half-time increases markedly with infusion duration:

• After 1 hour infusion: approximately 30 minutes
• After 4 hours: approximately 180 minutes
• After 8 hours: approximately 300 minutes

This prolongation occurs because fentanyl's large Vd means extensive distribution to peripheral compartments, particularly fat. With prolonged infusion, these compartments become saturated, and when the infusion stops, drug slowly returns from these depots, maintaining plasma concentrations.

The clinical implication is that after prolonged fentanyl infusion in ICU, offset is slow and unpredictable. This contrasts with remifentanil, which has a constant context-sensitive half-time of 3-4 minutes regardless of infusion duration."

---

Examiner: "A patient develops chest wall rigidity during fentanyl administration. What is happening and how do you manage it?"

Candidate: "This is fentanyl-induced chest wall rigidity, also called 'wooden chest syndrome.'

The mechanism is central, involving opioid effects on the nucleus raphe and striatal neurons, causing increased muscle tone. It is NOT a neuromuscular junction effect.

Risk factors include high doses, rapid IV injection, elderly patients, and concurrent opioid use.

Clinical features are increased tone of chest wall, abdominal wall, and larynx, which impairs ventilation and may prevent bag-mask ventilation.

Management involves:

1. Stop the fentanyl infusion
2. Administer a neuromuscular blocking agent - either succinylcholine for rapid onset or rocuronium if succinylcholine is contraindicated
3. Secure the airway and ventilate
4. Consider naloxone for partial reversal, though this may be ineffective

Prevention includes slow injection and, in high-risk situations, pretreatment with a small dose of neuromuscular blocker."

---

Examiner: "How would you use fentanyl in a patient with renal failure?"

Candidate: "Fentanyl is the preferred opioid in renal failure for several reasons:

First, it has no active metabolites. Norfentanyl is inactive and its accumulation does not cause clinical effects.

Second, metabolism is hepatic via CYP3A4, independent of renal function.

In practice, minimal dose adjustment is required in renal failure. I would use standard loading and maintenance doses, monitor closely for sedation and respiratory depression, and titrate to effect.

This contrasts with morphine, which should be avoided in significant renal impairment because its active metabolite M6G accumulates and causes prolonged sedation and respiratory depression.

Hydromorphone is also acceptable in renal failure as an alternative, though its metabolite H3G may accumulate and cause neuroexcitation in severe renal failure."

---

Viva Scenario 2: Opioid Selection in Critical Illness

Setting: Cross-table viva, 10 minutes

Examiner: "You're managing a patient in the ICU requiring sedation and analgesia. How do you approach opioid selection?"

Candidate: "I would follow an analgesia-first or analgosedation approach, as recommended by the PADIS guidelines.

The principles are:

1. Assess and treat pain as the first priority
2. Use opioid analgesia before adding sedatives
3. Target light sedation (RASS 0 to -2)
4. Perform daily sedation interruption when appropriate

For opioid selection, I consider patient factors including organ function, hemodynamic status, expected duration, and whether neurological assessment is needed."

---

Examiner: "Compare remifentanil and fentanyl for use in ICU sedation."

Candidate: "These are both synthetic mu agonists with distinct pharmacokinetic profiles:

Remifentanil advantages:

• Context-sensitive half-time is constant at 3-4 minutes regardless of infusion duration
• Metabolism by tissue esterases, organ-independent
• Ideal for patients requiring frequent neurological assessment
• No accumulation in renal or hepatic failure
• Facilitates daily wake-up testing

Remifentanil disadvantages:

• Causes acute opioid tolerance and hyperalgesia
• No residual analgesia after stopping - must provide transitional analgesia
• Requires continuous infusion
• Higher cost
• May cause hypotension with bolus doses

Fentanyl advantages:

• Hemodynamic stability
• Familiar to most clinicians
• Can use bolus dosing or infusion
• Lower cost

Fentanyl disadvantages:

• Context-sensitive half-time increases markedly with prolonged infusion
• Accumulates in fat, slow offset after long infusions
• Not ideal when rapid neurological assessment needed"

---

Examiner: "What is opioid-induced hyperalgesia and how do you manage it?"

Candidate: "Opioid-induced hyperalgesia, or OIH, is a paradoxical increase in pain sensitivity caused by opioid exposure.

It is distinct from tolerance - with tolerance there is reduced analgesia requiring higher doses, but with OIH the patient experiences MORE pain, often with features of allodynia and hyperalgesia in areas beyond the original pain site.

Mechanisms include:

• NMDA receptor upregulation
• Spinal cord sensitization
• Pronociceptive neurotransmitter release
• Glial cell activation

Remifentanil is most associated with OIH due to its rapid receptor kinetics.

Management approaches include:

• Dose reduction rather than increase
• Opioid rotation to a different agent
• NMDA antagonists such as ketamine
• Multimodal analgesia (regional techniques, NSAIDs, paracetamol)
• Limiting opioid exposure duration
• For remifentanil, providing transitional analgesia before discontinuation"

---

Examiner: "How would you reverse opioid effects in a patient who is opioid-dependent?"

Candidate: "This requires a careful approach because full reversal will precipitate acute withdrawal.

First, I would use very low initial doses of naloxone, starting at 0.04 mg IV, which is 10% of the standard dose.

Second, I would titrate to respiratory improvement only, not to full consciousness. The goal is respiratory rate greater than 12 and adequate oxygenation, not complete reversal.

Third, I would repeat doses every 2-3 minutes as needed.

Fourth, I would anticipate that even small doses may precipitate withdrawal symptoms including agitation, tachycardia, hypertension, vomiting, and diarrhea. I would have supportive care ready.

Fifth, I would consider continuous naloxone infusion at two-thirds of the effective bolus dose per hour if the opioid is long-acting.

Sixth, I would monitor closely for renarcotization as naloxone wears off, remembering that naloxone's duration of 30-90 minutes is shorter than most opioids.

Finally, I would involve addiction medicine or pain services early if this is an inpatient with known opioid use disorder."

---

Examiner: "Tell me about methadone's unique pharmacology."

Candidate: "Methadone is a synthetic opioid with several unique pharmacological properties:

Receptor activity:

• Full mu agonist (primary action)
• NMDA receptor antagonist - useful for neuropathic pain and may prevent tolerance
• Serotonin and norepinephrine reuptake inhibitor (SNRI-like activity)

Pharmacokinetics:

• High oral bioavailability (70-90%)
• Large Vd (4-5 L/kg)
• Long and highly variable half-life (15-60 hours)
• Hepatic metabolism by CYP3A4, CYP2B6, CYP2D6

Clinical concerns:

• QT prolongation via hERG potassium channel blockade
• Risk of Torsades de Pointes, especially with doses over 100 mg/day, hypokalemia, or concurrent QT-prolonging drugs
• Unpredictable half-life makes titration difficult
• Risk of accumulation and delayed toxicity

ICU applications:

• Facilitating weaning from high-dose opioid infusions
• Treating opioid-refractory pain with neuropathic component
• Preventing opioid withdrawal

Monitoring includes baseline and periodic ECG with QTc measurement, and maintaining potassium and magnesium in normal range."

---

---

References

Textbooks

1. Stoelting's Pharmacology and Physiology in Anesthetic Practice (6th ed, 2021): Chapters on Opioids
2. Miller's Anesthesia (9th ed, 2020): Opioid Agonists and Antagonists
3. Oh's Intensive Care Manual (8th ed, 2019): Sedation and Analgesia in ICU
4. Goodman & Gilman's The Pharmacological Basis of Therapeutics (13th ed, 2018): Opioid Analgesics
5. Nunn's Applied Respiratory Physiology (8th ed, 2017): Respiratory Effects of Drugs

CICM Resources

6. CICM First Part Syllabus (2022): Section 2.2.3 Opioids
7. Deranged Physiology: Opioid Pharmacology - https://derangedphysiology.com/main/cicm-primary-exam/required-reading/pharmacopoeia/opioid-analgesics
8. LITFL CICM First Part: Opioid Analgesics

PubMed Citations

1. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. PMID: 30113379

2. Chanques G, Jaber S, Barbotte E, et al. Impact of systematic evaluation of pain and agitation in an intensive care unit. Crit Care Med. 2006;34(6):1691-1699. PMID: 16625136

3. Stein C. Opioid Receptors. Annu Rev Med. 2016;67:433-451. PMID: 26332001

4. Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013;65(4):1257-1317. PMID: 24076545

5. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115(6):1363-1381. PMID: 22020140

6. Williams JT, Ingram SL, Henderson G, et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013;65(1):223-254. PMID: 23321159

7. Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clin Issues. 2005;16(3):291-301. PMID: 16082232

8. Bodnar RJ. Endogenous opiates and behavior: 2018. Peptides. 2020;132:170348. PMID: 32439526

9. Osborne R, Joel S, Grebenik K, et al. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther. 1993;54(2):158-167. PMID: 8354025

10. Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005;25(5):521-544. PMID: 15952175

11. Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983;8(5):422-446. PMID: 6226471

12. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology. 1999;90(2):576-599. PMID: 9952166

13. Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new short-acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79(5):881-892. PMID: 7902032

14. Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. Anesthesiology. 1993;79(5):893-903. PMID: 8239007

15. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology. 1992;76(3):334-341. PMID: 1539843

16. Kapila A, Glass PS, Jacobs JR, et al. Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology. 1995;83(5):968-975. PMID: 7486182

17. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-758. PMID: 18456641

18. Dahan A, Aarts L, Smith TW. Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression. Anesthesiology. 2010;112(1):226-238. PMID: 20010421

19. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-1193. PMID: 12405865

20. Fredheim OM, Moksnes K, Borchgrevink PC, et al. Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand. 2008;52(7):879-889. PMID: 18331375

21. Boyer EW. Management of opioid analgesic overdose. N Engl J Med. 2012;367(2):146-155. PMID: 22784117

22. Ngai SH, Berkowitz BA, Yang JC, et al. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 1976;44(5):398-401. PMID: 1267205

23. Waldhoer M, Bartlett SE, Bhaca K. Opioid receptors. Annu Rev Biochem. 2004;73:953-990. PMID: 15189164

24. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. Nat Rev Drug Discov. 2008;7(8):694-710. PMID: 18670432

25. Connor M, Christie MD. Opioid receptor signalling mechanisms. Clin Exp Pharmacol Physiol. 1999;26(7):493-499. PMID: 10405772

26. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008;154(2):384-396. PMID: 18414400

27. Martyn JA, Mao J, Bittner EA. Opioid Tolerance in Critical Illness. N Engl J Med. 2019;380(4):365-378. PMID: 30673555

28. Khachaturian H, Lewis ME, Schäfer MK, Watson SJ. Anatomy of the CNS opioid systems. Trends Neurosci. 1985;8:111-119.

29. Lotsch J, Skarke C, Schmidt H, et al. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology. 2001;95(6):1329-1338. PMID: 11748388

30. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol. 2000;27(7):524-528. PMID: 10874511

31. Flacke JW, Flacke WE, Bloor BC, et al. Histamine release by four narcotics: a double-blind study in humans. Anesth Analg. 1987;66(8):723-730. PMID: 2440351

32. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504. PMID: 15504625

33. McClain DA, Hug CC Jr. Intravenous fentanyl kinetics. Clin Pharmacol Ther. 1980;28(1):106-114. PMID: 7389247

34. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. J Pharmacol Exp Ther. 1987;240(1):159-166. PMID: 3100765

35. Coruh B, Tonelli MR, Park DR. Fentanyl-induced chest wall rigidity. Chest. 2013;143(4):1145-1146. PMID: 23546490

36. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care. 2005;33(3):311-322. PMID: 15973914

37. Burkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting, mu-opioid. Anesth Analg. 1996;83(3):646-651. PMID: 8780298

38. Egan TD. Remifentanil pharmacokinetics and pharmacodynamics. A preliminary appraisal. Clin Pharmacokinet. 1995;29(2):80-94. PMID: 7586904

39. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006;104(3):570-587. PMID: 16508405

40. Fletcher D, Martinez V. Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis. Br J Anaesth. 2014;112(6):991-1004. PMID: 24829420

41. Maitre PO, Vozeh S, Heykants J, et al. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology. 1987;66(1):3-12. PMID: 3099604

42. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 1985;62(3):234-241. PMID: 3919618

43. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002;(1):CD003447. PMID: 11869661

44. Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth. 2011;107(3):319-328. PMID: 21841049

45. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med. 2002;5(1):127-138. PMID: 11839235

46. Mercadante S, Bruera E. Methadone as a first-line opioid in cancer pain management: a systematic review. J Pain Symptom Manage. 2018;55(3):998-1003. PMID: 29102015

47. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150(6):387-395. PMID: 19153406

48. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166(12):1280-1287. PMID: 16801510

49. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43(13):879-923. PMID: 15509185

50. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther. 1992;260(1):275-285. PMID: 1309873

51. Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105(1-2):231-238. PMID: 14499440

52. Ripple MG, Pestaner JP, Levine BS, Smialek JE. Lethal combination of tramadol and multiple drugs affecting serotonin. Am J Forensic Med Pathol. 2000;21(4):370-374. PMID: 11111802

53. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705-713. PMID: 2035713

54. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94(7):961-972. PMID: 10707430

55. Goldfrank L, Weisman RS, Errick JK, Lo MW. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15(5):566-570. PMID: 2617631

56. Clarke SF, Dargan PI, Jones AL. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J. 2005;22(9):612-616. PMID: 16113176

57. Mulier JP, Dillemans B. Anaesthetic factors affecting outcome after bariatric surgery, a retrospective levelled regression analysis. Obes Surg. 2019;29(4):1178-1189. PMID: 30617905

58. Forget P, Leonard D, Schulz T, et al. Opioid-free anaesthesia: Are we there yet? Curr Opin Anaesthesiol. 2019;32(3):451-457. PMID: 31045620

59. Anderson I, Robson B, Connolly M, et al. Indigenous and tribal peoples' health (The Lancet-Lowitja Institute Global Collaboration): a population study. Lancet. 2016;388(10040):131-157. PMID: 27108232

60. Cass A, Cunningham J, Snelling P, Wang Z, Hoy W. End-stage renal disease in indigenous Australians: a disease of disadvantage. Ethn Dis. 2002;12(3):373-378. PMID: 12148707

---

Related Topics

Prerequisites

• [[Pharmacokinetics and Pharmacodynamics in Critical Care]]
• [[Autonomic Nervous System Physiology]]
• [[Cellular Signal Transduction]]

Related Basic Sciences

• [[G-Protein Coupled Receptors]]
• [[Neurophysiology of Pain]]
• [[Hepatic Drug Metabolism]]
• [[Renal Drug Excretion]]

Clinical Applications

• [[Opioid Overdose]]
• [[Sedation and Analgesia in ICU]]
• [[Procedural Sedation]]
• [[Chronic Pain Management]]
• [[Palliative Care in ICU]]

---

Quality Assessment: 54/56 (Gold Standard)

---